Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
62.3M
-
Number of holders
-
40
-
Total 13F shares, excl. options
-
28M
-
Shares change
-
-3.51M
-
Total reported value, excl. options
-
$18.6M
-
Value change
-
-$4.59M
-
Number of buys
-
19
-
Number of sells
-
-11
-
Price
-
$0.66
Significant Holders of Elevation Oncology, Inc. - Common stock, par value $0.0001 per share (ELEV) as of Q3 2023
45 filings reported holding ELEV - Elevation Oncology, Inc. - Common stock, par value $0.0001 per share as of Q3 2023.
Elevation Oncology, Inc. - Common stock, par value $0.0001 per share (ELEV) has 40 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28M shares
of 62.3M outstanding shares and own 44.99% of the company stock.
Largest 10 shareholders include TANG CAPITAL MANAGEMENT LLC (4M shares), MILLENNIUM MANAGEMENT LLC (3.03M shares), venBio Partners LLC (2.91M shares), Aisling Capital Management LP (2.83M shares), Qiming U.S. Ventures Management, LLC (2.37M shares), BVF INC/IL (2.31M shares), ORBIMED ADVISORS LLC (1.5M shares), Ikarian Capital, LLC (1.17M shares), VANGUARD GROUP INC (1.07M shares), and ExodusPoint Capital Management, LP (1M shares).
This table shows the top 40 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.